新股消息 | 眼科生物科技公司拨康视云四次递表港交所 2024年亏损约0.99亿美元

Core Viewpoint - Cloudbreak Pharma Inc. has submitted its fourth listing application to the Hong Kong Stock Exchange, with previous applications submitted in November 2023, May 2024, and December 2024 [1]. Company Overview - Cloudbreak Pharma is a clinical-stage ophthalmic biotechnology company focused on developing various therapies for eye diseases. The company was established in the U.S. in September 2015 and registered in the Cayman Islands in November 2020 [4]. - The company has two core products, CBT-001 and CBT-009, both of which are self-developed. CBT-001 is aimed at treating pterygium, and CBT-009 targets myopia in adolescents aged 5 to 19 [4][5]. Product Pipeline - Cloudbreak Pharma has established an innovative pipeline consisting of four clinical-stage candidates and four preclinical candidates, all of which are self-developed. The pipeline covers major diseases affecting both the anterior and posterior segments of the eye [5]. - The clinical-stage candidates include CBT-001 and CBT-009, while the preclinical candidates include CBT-007, CBT-199, CBT-145, and CBT-011, targeting various eye conditions [6][7]. Market Potential - The global ophthalmic drug market has grown from $33.7 billion in 2019 to $39.6 billion in 2023, with a compound annual growth rate (CAGR) of 4.1%. It is projected to reach $53 billion by 2028 and $70.3 billion by 2033, with respective CAGRs of 6.0% and 5.8% during the specified periods [7]. Financial Performance - Cloudbreak Pharma reported losses of approximately $67 million, $129 million, and $99 million for the fiscal years 2022, 2023, and 2024, respectively. The projected revenue for 2024 is around $10 million [8].